|
1
|
Bray F, Ferlay J, Soerjomataram I, Siegel
RL, Torre LA and Jemal A: Global cancer statistics 2018: GLOBOCAN
estimates of incidence and mortality worldwide for 36 cancers in
185 countries. CA Cancer J Clin. 68:394–424. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Ferraldeschi R, Welti J, Luo J, Attard G
and de Bono JS: Targeting the androgen receptor pathway in
castration-resistant prostate cancer: Progresses and prospects.
Oncogene. 34:1745–1757. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Sun S, Sprenger CC, Vessella RL, Haugk K,
Soriano K, Mostaghel EA, Page ST, Coleman IM, Nguyen HM, Sun H, et
al: Castration resistance in human prostate cancer is conferred by
a frequently occurring androgen receptor splice variant. J Clin
Invest. 120:2715–2730. 2010. View
Article : Google Scholar : PubMed/NCBI
|
|
4
|
Noble RL: The development of prostatic
adenocarcinoma in Nb rats following prolonged sex hormone
administration. Cancer Res. 37:1929–1933. 1977.PubMed/NCBI
|
|
5
|
Egan A, Dong Y, Zhang H, Qi Y, Balk SP and
Sartor O: Castration-resistant prostate cancer: Adaptive responses
in the androgen axis. Cancer Treat Rev. 40:426–433. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Centenera MM, Harris JM, Tilley WD and
Butler LM: The contribution of different androgen receptor domains
to receptor dimerization and signaling. Mol Endocrinol.
22:2373–2382. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Chandrasekar T, Yang JC, Gao AC and Evans
CP: Mechanisms of resistance in castration-resistant prostate
cancer (CRPC). Transl Androl Urol. 4:365–380. 2015.PubMed/NCBI
|
|
8
|
Hu R, Dunn TA, Wei S, Isharwal S, Veltri
RW, Humphreys E, Han M, Partin AW, Vessella RL, Isaacs WB, et al:
Ligand-independent androgen receptor variants derived from splicing
of cryptic exons signify hormone-refractory prostate cancer. Cancer
Res. 69:16–22. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Dolma S, Lessnick SL, Hahn WC and
Stockwell BR: Identification of genotype-selective antitumor agents
using synthetic lethal chemical screening in engineered human tumor
cells. Cancer Cell. 3:285–296. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Dixon SJ, Lemberg KM, Lamprecht MR, Skouta
R, Zaitsev EM, Gleason CE, Patel DN, Bauer AJ, Cantley AM, Yang WS,
et al: Ferroptosis: An iron-dependent form of nonapoptotic cell
death. Cell. 149:1060–1072. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Yagoda N, von Rechenberg M, Zaganjor E,
Bauer AJ, Yang WS, Fridman DJ, Wolpaw AJ, Smukste I, Peltier JM,
Boniface JJ, et al: RAS-RAF-MEK-dependent oxidative cell death
involving voltage-dependent anion channels. Nature. 447:864–868.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Dixon SJ, Patel DN, Welsch M, Skouta R,
Lee ED, Hayano M, Thomas AG, Gleason CE, Tatonetti NP, Slusher BS
and Stockwell BR: Pharmacological inhibition of cystine-glutamate
exchange induces endoplasmic reticulum stress and ferroptosis.
Elife. 3:e025232014. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Sato M, Kusumi R, Hamashima S, Kobayashi
S, Sasaki S, Komiyama Y, Izumikawa T, Conrad M, Bannai S and Sato
H: The ferroptosis inducer erastin irreversibly inhibits system xc-
and synergizes with cisplatin to increase cisplatin's cytotoxicity
in cancer cells. Sci Rep. 8:9682018. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Yu Y, Xie Y, Cao L, Yang L, Yang M, Lotze
MT, Zeh HJ, Kang R and Tang D: The ferroptosis inducer erastin
enhances sensitivity of acute myeloid leukemia cells to
chemotherapeutic agents. Mol Cell Oncol. 2:e10545492015. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Kwon MY, Park E, Lee SJ and Chung SW: Heme
oxygenase-1 accelerates erastin-induced ferroptotic cell death.
Oncotarget. 6:24393–24403. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Sun X, Ou Z, Chen R, Niu X, Chen D, Kang R
and Tang D: Activation of the p62-Keap1-NRF2 pathway protects
against ferroptosis in hepatocellular carcinoma cells. Hepatology.
63:173–184. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Hasegawa M, Takahashi H, Rajabi H, Alam M,
Suzuki Y, Yin L, Tagde A, Maeda T, Hiraki M, Sukhatme VP and Kufe
D: Functional interactions of the cystine/glutamate antiporter,
CD44v and MUC1-C oncoprotein in triple-negative breast cancer
cells. Oncotarget. 7:11756–11769. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Roh JL, Kim EH, Jang HJ, Park JY and Shin
D: Induction of ferroptotic cell death for overcoming cisplatin
resistance of head and neck cancer. Cancer Lett. 381:96–103. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Dong Y, Zhang H, Hawthorn L, Ganther HE
and Ip C: Delineation of the molecular basis for selenium-induced
growth arrest in human prostate cancer cells by oligonucleotide
array. Cancer Res. 63:52–59. 2003.PubMed/NCBI
|
|
20
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Gordon CA, Gulzar ZG and Brooks JD: NUSAP1
expression is upregulated by loss of RB1 in prostate cancer cells.
Prostate. 75:517–526. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Wu S, Zhao F, Zhao J, Li H, Chen J, Xia Y,
Wang J, Zhao B, Zhao S and Li N: Dioscin improves postmenopausal
osteoporosis through inducing bone formation and inhibiting
apoptosis in ovariectomized rats. Biosci Trends. 13:394–401. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Zheng J, Zhao S, Yu X, Huang S and Liu HY:
Simultaneous targeting of CD44 and EpCAM with a bispecific aptamer
effectively inhibits intraperitoneal ovarian cancer growth.
Theranostics. 7:1373–1388. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Dehm SM, Schmidt LJ, Heemers HV, Vessella
RL and Tindall DJ: Splicing of a novel androgen receptor exon
generates a constitutively active androgen receptor that mediates
prostate cancer therapy resistance. Cancer Res. 68:5469–5477. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Kita K, Shiota M, Tanaka M, Otsuka A,
Matsumoto M, Kato M, Tamada S, Iwao H, Miura K, Nakatani T and
Tomita S: Heat shock protein 70 inhibitors suppress androgen
receptor expression in LNCaP95 prostate cancer cells. Cancer Sci.
108:1820–1827. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Zhao N, Peacock SO, Lo CH, Heidman LM,
Rice MA, Fahrenholtz CD, Greene AM, Magani F, Copello VA, Martinez
MJ, et al: Arginine vasopressin receptor 1a is a therapeutic target
for castration-resistant prostate cancer. Sci Transl Med.
11:eaaw46362019. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Xu D, Zhan Y, Qi Y, Cao B, Bai S, Xu W,
Gambhir SS, Lee P, Sartor O, Flemington EK, et al: Androgen
receptor splice variants dimerize to transactivate target genes.
Cancer Res. 75:3663–3671. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Paschalis A, Sharp A, Welti JC, Neeb A,
Raj GV, Luo J, Plymate SR and de Bono JS: Alternative splicing in
prostate cancer. Nat Rev Clin Oncol. 15:663–675. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Thadani-Mulero M, Portella L, Sun S, Sung
M, Matov A, Vessella RL, Corey E, Nanus DM, Plymate SR and
Giannakakou P: Androgen receptor splice variants determine taxane
sensitivity in prostate cancer. Cancer Res. 74:2270–2282. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Darshan MS, Loftus MS, Thadani-Mulero M,
Levy BP, Escuin D, Zhou XK, Gjyrezi A, Chanel-Vos C, Shen R, Tagawa
ST, et al: Taxane-induced blockade to nuclear accumulation of the
androgen receptor predicts clinical responses in metastatic
prostate cancer. Cancer Res. 71:6019–6029. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Zhu ML, Horbinski CM, Garzotto M, Qian DZ,
Beer TM and Kyprianou N: Tubulin-targeting chemotherapy impairs
androgen receptor activity in prostate cancer. Cancer Res.
70:7992–8002. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Bai S, Zhang BY and Dong Y: Impact of
taxanes on androgen receptor signaling. Asian J Androl. 21:249–252.
2019. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Zhao Y, Li Y, Zhang R, Wang F, Wang T and
Jiao Y: The role of erastin in ferroptosis and its prospects in
cancer therapy. Onco Targets Ther. 13:5429–5441. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Huo H, Zhou Z, Qin J, Liu W, Wang B and Gu
Y: Erastin disrupts mitochondrial permeability transition pore
(mPTP) and induces apoptotic death of colorectal cancer cells. PLoS
One. 11:e01546052016. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Yu M, Gai C, Li Z, Ding D, Zheng J, Zhang
W, Lv S and Li W: Targeted exosome-encapsulated erastin induced
ferroptosis in triple negative breast cancer cells. Cancer Sci.
110:3173–3182. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Antonarakis ES, Lu C, Wang H, Luber B,
Nakazawa M, Roeser JC, Chen Y, Mohammad TA, Chen Y, Fedor HL, et
al: AR-V7 and resistance to enzalutamide and abiraterone in
prostate cancer. N Engl J Med. 371:1028–1038. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Li Y, Chan SC, Brand LJ, Hwang TH,
Silverstein KA and Dehm SM: Androgen receptor splice variants
mediate enzalutamide resistance in castration-resistant prostate
cancer cell lines. Cancer Res. 73:483–489. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Ponnusamy S, Coss CC, Thiyagarajan T,
Watts K, Hwang DJ, He Y, Selth LA, McEwan IJ, Duke CB, Pagadala J,
et al: Novel selective agents for the degradation of androgen
receptor variants to treat castration-resistant prostate cancer.
Cancer Res. 77:6282–6298. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Yamashita S, Lai KP, Chuang KL, Xu D,
Miyamoto H, Tochigi T, Pang ST, Li L, Arai Y, Kung HJ, et al:
ASC-J9 suppresses castration-resistant prostate cancer growth
through degradation of full-length and splice variant androgen
receptors. Neoplasia. 14:74–83. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Zhang G, Liu X, Li J, Ledet E, Alvarez X,
Qi Y, Fu X, Sartor O, Dong Y and Zhang H: Androgen receptor splice
variants circumvent AR blockade by microtubule-targeting agents.
Oncotarget. 6:23358–23371. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Shan X, Danet-Desnoyers G, Aird F, Kandela
I, Tsui R, Perfito N and Iorns E: Replication study: Androgen
receptor splice variants determine taxane sensitivity in prostate
cancer. PeerJ. 6:e46612018. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Cristofani R, Montagnani Marelli M,
Cicardi ME, Fontana F, Marzagalli M, Limonta P, Poletti A and
Moretti RM: Dual role of autophagy on docetaxel-sensitivity in
prostate cancer cells. Cell Death Dis. 9:8892018. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Wang L, Chen H, Liu F, Madigan MC, Power
CA, Hao J, Patterson KI, Pourgholami MH, O'Brien PM, Perkins AC and
Li Y: Monoclonal antibody targeting MUC1 and increasing sensitivity
to docetaxel as a novel strategy in treating human epithelial
ovarian cancer. Cancer Lett. 300:122–133. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Zhang D, Cui Y, Niu L, Xu X, Tian K, Young
CYF, Lou H and Yuan H: Regulation of SOD2 and β-arrestin1 by
interleukin-6 contributes to the increase of IGF-1R expression in
docetaxel resistant prostate cancer cells. Eur J Cell Biol.
93:289–298. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Shan W, Zhong W, Zhao R and Oberley TD:
Thioredoxin 1 as a subcellular biomarker of redox imbalance in
human prostate cancer progression. Free Radic Biol Med.
49:2078–2087. 2010. View Article : Google Scholar : PubMed/NCBI
|
